152 related articles for article (PubMed ID: 27841034)
1. Targeting pancreatic expressed PAX genes for the treatment of diabetes mellitus and pancreatic neuroendocrine tumors.
Martin-Montalvo A; Lorenzo PI; López-Noriega L; Gauthier BR
Expert Opin Ther Targets; 2017 Jan; 21(1):77-89. PubMed ID: 27841034
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors.
Lorenzo PI; Jimenez Moreno CM; Delgado I; Cobo-Vuilleumier N; Meier R; Gomez-Izquierdo L; Berney T; Garcia-Carbonero R; Rojas A; Gauthier BR
Histochem Cell Biol; 2011 Nov; 136(5):595-607. PubMed ID: 21932072
[TBL] [Abstract][Full Text] [Related]
3. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens.
Haynes CM; Sangoi AR; Pai RK
Cancer Cytopathol; 2011 Jun; 119(3):193-201. PubMed ID: 21328566
[TBL] [Abstract][Full Text] [Related]
4. PAX proteins and their role in pancreas.
Panneerselvam A; Kannan A; Mariajoseph-Antony LF; Prahalathan C
Diabetes Res Clin Pract; 2019 Sep; 155():107792. PubMed ID: 31325538
[TBL] [Abstract][Full Text] [Related]
5. PAX6 is expressed in pancreatic adenocarcinoma and is downregulated during induction of terminal differentiation.
Lang D; Mascarenhas JB; Powell SK; Halegoua J; Nelson M; Ruggeri BA
Mol Carcinog; 2008 Feb; 47(2):148-56. PubMed ID: 17849422
[TBL] [Abstract][Full Text] [Related]
6. The Diagnostic Utility of PAX8 for Neuroendocrine Tumors: An Immunohistochemical Reappraisal.
Liau JY; Tsai JH; Jeng YM; Kuo KT; Huang HY; Liang CW; Yang CY
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):57-63. PubMed ID: 25710581
[TBL] [Abstract][Full Text] [Related]
7. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
Pea A; Hruban RH; Wood LD
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
[TBL] [Abstract][Full Text] [Related]
8. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.
Sangoi AR; Ohgami RS; Pai RK; Beck AH; McKenney JK; Pai RK
Mod Pathol; 2011 Mar; 24(3):412-24. PubMed ID: 20890270
[TBL] [Abstract][Full Text] [Related]
9. Lack of in vivo functional compensation between Pax family groups II and III in rodents.
Hayashi S; Rocancourt D; Buckingham M; Relaix F
Mol Biol Evol; 2011 Oct; 28(10):2787-98. PubMed ID: 21512107
[TBL] [Abstract][Full Text] [Related]
10. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival.
Muratovska A; Zhou C; He S; Goodyer P; Eccles MR
Oncogene; 2003 Sep; 22(39):7989-97. PubMed ID: 12970747
[TBL] [Abstract][Full Text] [Related]
11. Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.
Lai JP; Mertens RB; Mirocha J; Koo J; Venturina M; Chung F; Mendez AB; Kahn M; Dhall D
Endocr Pathol; 2015 Mar; 26(1):54-62. PubMed ID: 25433656
[TBL] [Abstract][Full Text] [Related]
12. Pax-QNR/Pax-6, a paired box- and homeobox-containing gene expressed in neurons, is also expressed in pancreatic endocrine cells.
Turque N; Plaza S; Radvanyi F; Carriere C; Saule S
Mol Endocrinol; 1994 Jul; 8(7):929-38. PubMed ID: 7984154
[TBL] [Abstract][Full Text] [Related]
13. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
Long KB; Srivastava A; Hirsch MS; Hornick JL
Am J Surg Pathol; 2010 May; 34(5):723-9. PubMed ID: 20414099
[TBL] [Abstract][Full Text] [Related]
14. The Pax gene family: Highlights from cephalopods.
Navet S; Buresi A; Baratte S; Andouche A; Bonnaud-Ponticelli L; Bassaglia Y
PLoS One; 2017; 12(3):e0172719. PubMed ID: 28253300
[TBL] [Abstract][Full Text] [Related]
15. Animal models and cell lines of pancreatic neuroendocrine tumors.
Babu V; Paul N; Yu R
Pancreas; 2013 Aug; 42(6):912-23. PubMed ID: 23851429
[TBL] [Abstract][Full Text] [Related]
16. Value of PAX 8 immunostaining in tumor diagnosis: a review and update.
Ordóñez NG
Adv Anat Pathol; 2012 May; 19(3):140-51. PubMed ID: 22498579
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic neuroendocrine tumors: pathologic and molecular characteristics.
Shi C; Klimstra DS
Semin Diagn Pathol; 2014 Nov; 31(6):498-511. PubMed ID: 25441311
[TBL] [Abstract][Full Text] [Related]
18. Identification of molecular markers specific for pancreatic neuroendocrine tumors by genetic profiling of core biopsies.
Bloomston M; Durkin A; Yang I; Rojiani M; Rosemurgy AS; Enkmann S; Yeatman TJ; Zervos EE
Ann Surg Oncol; 2004 Apr; 11(4):413-9. PubMed ID: 15070602
[TBL] [Abstract][Full Text] [Related]
19. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.
Falconi M; Eriksson B; Kaltsas G; Bartsch DK; Capdevila J; Caplin M; Kos-Kudla B; Kwekkeboom D; Rindi G; Klöppel G; Reed N; Kianmanesh R; Jensen RT;
Neuroendocrinology; 2016; 103(2):153-71. PubMed ID: 26742109
[No Abstract] [Full Text] [Related]
20. Phylogenetic analysis and expression patterns of Pax genes in the onychophoran Euperipatoides rowelli reveal a novel bilaterian Pax subfamily.
Franke FA; Schumann I; Hering L; Mayer G
Evol Dev; 2015; 17(1):3-20. PubMed ID: 25627710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
